Trial Profile
A Phase 3, Multicenter, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Daratumumab (Primary) ; Melphalan (Primary) ; Prednisone (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms OCTANS
- Sponsors Janssen Research & Development
- 27 Feb 2024 Planned End Date changed from 31 May 2024 to 31 Mar 2024.
- 12 Dec 2023 Primary endpoint has been met. (Achievement of a very good partial response (VGPR) or better) , according to presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 According to Results presented at the 65th American Society of Hematology Annual Meeting and Exposition, Per a protocol amendment, patients receiving daratumumab IV were permitted to switch to daratumumab SC 1,800 mg (same schedule as IV) on Day 1 of any cycle.